PExA (PEXA) Q3 2025 earnings summary

Executive summary

• Revenue for Q3 2025 was 44,489 SEK, up from 31,503 SEK year-over-year; nine-month revenue reached 357,069 SEK, up from 251,201 SEK.

• Net loss after financial items for Q3 was -2,574,777 SEK (vs. -2,260,358 SEK); nine-month net loss was -7,138,751 SEK (vs. -7,210,668 SEK).

• Fully guaranteed rights issue raised 9.9 MSEK, securing funding for strategic development.

• Focus remains on long-term value creation, technology development, and expansion into diagnostic applications.

Financial highlights

• Q3 net sales increased 41% year-over-year; nine-month sales up 42%.

• Q3 net loss widened to -2.57 MSEK; nine-month net loss slightly improved to -7.14 MSEK.

• Cash and cash equivalents at period end were 8.06 MSEK, up from 7.77 MSEK.

• Operating cash flow for Q3 was 6.37 MSEK; nine-month operating cash flow was 2.46 MSEK.

• Equity ratio at period end was 82.5% (down from 88.4%).

Outlook and guidance

• Funding from the rights issue enables continued development in three strategic focus areas.

• Ongoing efforts to expand from research to clinical diagnostics, especially in lung cancer.

• Long-term goal is to enable earlier detection of lung diseases and expand into broader diagnostic markets.